We are live on ! Find out more
BTAI icon

BioXcel Therapeutics
BTAI

70 hedge funds and large institutions have $117M invested in BioXcel Therapeutics in 2020 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 16 increasing their positions, 17 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

350% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 8

85% more capital invested

Capital invested by funds: $63.3M → $117M (+$53.5M)

63% more funds holding

Funds holding: 43 → 70 (+27)

0.36% more ownership

Funds ownership: 1.5% → 1.86% (+0.36%)

6% less repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 17

7% less call options, than puts

Call options by funds: $4.06M | Put options by funds: $4.36M

Holders
70
Holders Change
+27
Holders Change %
+62.79%
% of All Funds
1.54%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
36
Increased
16
Reduced
17
Closed
8
Calls
$4.06M
Puts
$4.36M
Net Calls
-$303K
Net Calls Change
-$303K

Top Buyers

Rank Fund Capital Flow
1
IC
Ikarian Capital
Texas
+$12M
2
ACP
Acuta Capital Partners
California
+$7.08M
3
DCM
Driehaus Capital Management
Illinois
+$6.74M
4
Massachusetts Financial Services
Massachusetts Financial Services
Massachusetts
+$6.16M
5
APM
Avidity Partners Management
Texas
+$4.74M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$6.85M
2
AIM
Artemis Investment Management
United Kingdom
-$6.44M
3
California Public Employees Retirement System
California Public Employees Retirement System
California
-$4.77M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$3.73M
5
DAM
DLD Asset Management
New York
-$956K
Name Holding Trade Value Shares
Change 		Change in
Stake
IC
1
Ikarian Capital
Texas
$15.5M +$12M +33,459 +338%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$13.5M -$6.85M -19,069 -34%
BlackRock
3
BlackRock
New York
$11.2M +$2.22M +6,167 +25%
Vanguard Group
4
Vanguard Group
Pennsylvania
$11M +$2.31M +6,434 +27%
ACP
5
Acuta Capital Partners
California
$7.04M +$7.08M +19,688 New
DCM
6
Driehaus Capital Management
Illinois
$6.7M +$6.74M +18,746 New
Massachusetts Financial Services
7
Massachusetts Financial Services
Massachusetts
$6.13M +$6.16M +17,150 New
APM
8
Avidity Partners Management
Texas
$4.72M +$4.74M +13,188 New
N
9
Nuveen
North Carolina
$3.44M +$3.22M +8,966 +1,342%
Geode Capital Management
10
Geode Capital Management
Massachusetts
$3.03M +$1.27M +3,524 +71%
Northern Trust
11
Northern Trust
Illinois
$2.88M +$239K +664 +9%
State Street
12
State Street
Massachusetts
$2.82M +$589K +1,640 +26%
O
13
OrbiMed
New York
$2.4M +$2.41M +6,706 New
California Public Employees Retirement System
14
California Public Employees Retirement System
California
$2.31M -$4.77M -13,260 -67%
Federated Hermes
15
Federated Hermes
Pennsylvania
$1.97M +$1.98M +5,498 New
UBS Group
16
UBS Group
Switzerland
$1.93M -$147K -410 -7%
BFM
17
Boothbay Fund Management
New York
$1.9M +$1.32M +3,681 +224%
MAP
18
Moody Aldrich Partners
Massachusetts
$1.78M +$1.79M +4,978 New
Renaissance Technologies
19
Renaissance Technologies
New York
$1.62M -$53.9K -150 -3%
EGI
20
EAM Global Investors
California
$1.61M +$1.61M +4,490 New
EI
21
EAM Investors
California
$1.25M +$1.25M +3,486 New
Goldman Sachs
22
Goldman Sachs
New York
$1.12M +$1.12M +3,119 New
Bank of New York Mellon
23
Bank of New York Mellon
New York
$1.11M +$684K +1,902 +157%
Simplex Trading
24
Simplex Trading
Illinois
$950K +$956K +2,659 New
Group One Trading
25
Group One Trading
Illinois
$804K +$808K +2,249 New
1
2 3 4

BTAI Hedge Fund Activity: Q1 2020 in Review

70 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in BioXcel Therapeutics (BTAI) for Q1 2020, worth a combined $117M — up 85% from $63.3M a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new BTAI positions and 8 closed out — a net gain of 28 holders — while 16 added to existing stakes and 17 trimmed.

The largest buyer was Ikarian Capital, adding an estimated $12M. The largest seller was Fidelity Investments, cutting an estimated $6.85M.

  • 70 institutional investors held BioXcel Therapeutics (BTAI) as of Q1 2020, up from 43 in Q4 2019.
  • Funds reported $117M of BioXcel Therapeutics stock for Q1 2020, up 85% quarter-over-quarter.
  • 36 funds opened new BioXcel Therapeutics positions in Q1 2020 and 8 closed out, a net change of +28 holders.
  • The largest BioXcel Therapeutics buyer in Q1 2020 was Ikarian Capital, an estimated $12M added.
  • The largest BioXcel Therapeutics seller in Q1 2020 was Fidelity Investments, an estimated $6.85M sold.

Based on aggregated 13F filings for Q1 2020.